SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

OmniAb, Inc. OABIW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

OmniAb, Inc. (OABIW) is a Biotechnology company in the Healthcare sector, currently trading at $0.10. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 2 out of 7 criteria passed.

Valuation: OABIW trades at a trailing Price-to-Earnings (P/E) of -2.9 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.09.

Financials: revenue is $19M, -31.4%/yr average growth. Net income is $65M (loss), growing at -51.2%/yr. Net profit margin is -347% (negative). Gross margin is -18.2% (-90.7 pp trend).

Balance sheet: total debt is $20M against $267M equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 4.02 (strong liquidity). Debt-to-assets is 6.8%. Total assets: $301M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

OABIW SharesGrow Score Overview

56/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 0/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OABIW

OABIW trades at a trailing Price-to-Earnings (P/E) of -2.9 (S&P 500 average ~25). Forward PEG 0.09 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

OABIW: -31.4%/yr revenue is, -51.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet OABIW: Debt-to-Equity (D/E) ratio 0.08 (conservative), Current ratio is 4.02 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

No analyst coverage available for this stock.

OABIW: Net profit margin is -347%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.08-0.165

Volume3

Avg Volume (30D)3.47K

Market Cap$15.13M

Beta (1Y)0.86

Share Statistics

EPS (TTM)-0.57

Shares Outstanding$113.64M

IPO Date2021-09-30

Employees114

CEOMatthew W. Foehr

Financial Highlights & Ratios

Revenue (TTM)$18.67M

Gross Profit$-3.39M

EBITDA$-49.76M

Net Income$-64.78M

Operating Income$-71.52M

Total Cash$54.03M

Total Debt$20.33M

Net Debt$-5.19M

Total Assets$300.91M

Price / Earnings (P/E)-0.2

Price / Sales (P/S)0.81

Analyst Forecast

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS68218J1117

Price Chart

OABIW

OmniAb, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.08 52WK RANGE 0.17

People Also View

Orchestra BioMed Holdings, Inc.

Coherus Oncology, Inc.

Protara Therapeutics, Inc.

Heron Therapeutics, Inc.

Vor Biopharma Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message